Welcome

Australian Osteoporosis Therapeutics Markets

 

  • Research Code : 4B96-01-00-00-00
  • SKU : HC00140-AP-MR_02984
  • Share this :
  • Release Date : 13-Dec-2005
  • Region : Asia Pacific
  • Request Study Sample

Availability: In stock

Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, causing increased susceptibility to fractures and chronic bone pain. The main therapies for the treatment of osteoporosis are hormone replacement therapy (HRT), bisphosphonates and selective oestrogen receptor modulators (SERMs). A key driver for the market is the lack of effective drugs that have a good safety and side effect profile. With a few drugs expected to enter the market over the forecast period, competition is expected to intensify. Stratification of the market should happen, so that companies should be able to serve niche markets. The current leader however, is expected to remain the dominant provider of osteoporosis medications.
USD 3,950

* Required Fields

Pay By Invoice

Be the first to review this product

Related Research
WHY CHOOSE
FROST & SULLIVAN
RESEARCH ?

1. Primary Research

Our analysis is based on comprehensive primary research conducted with core market participants.

2. Global Coverage

Unparalleled coverage of geographies, our analyst & consultant teams are based in 42+ offices spanning the globe.

3. Breadth of Vertical Industries

We cover the broadest spectrum of markets to provide our clients with the most relevant analysis and transformational insights.

4. Visionary Innovation Research

With on-going transformational shifts, our visionary innovation research prepares you with information on key megatrends shaping the future of your industry.

5. Mega Trends

Mega Trends are global forces that transform business, societies and economies.

6. Convergence Research Coverage

Taking an approach of analysing a macro-to-micro impact, our convergence research helps you prepare against an impending 'Kodak moment'.